Your browser is no longer supported. Please, upgrade your browser.
Catalyst Biosciences, Inc.
Index- P/E- EPS (ttm)-3.01 Insider Own0.40% Shs Outstand31.35M Perf Week-8.49%
Market Cap143.20M Forward P/E- EPS next Y-2.10 Insider Trans0.00% Shs Float30.30M Perf Month9.72%
Income-77.30M PEG- EPS next Q-0.66 Inst Own64.50% Short Float2.72% Perf Quarter4.41%
Sales5.50M P/S26.04 EPS this Y36.20% Inst Trans-10.76% Short Ratio2.39 Perf Half Y-7.96%
Book/sh2.72 P/B1.74 EPS next Y22.50% ROA-72.30% Target Price- Perf Year10.75%
Cash/sh2.86 P/C1.66 EPS next 5Y- ROE-86.00% 52W Range3.72 - 7.55 Perf YTD-24.88%
Dividend- P/FCF- EPS past 5Y43.30% ROI- 52W High-37.22% Beta2.00
Dividend %- Quick Ratio6.20 Sales past 5Y64.30% Gross Margin-0.70% 52W Low27.42% ATR0.26
Employees36 Current Ratio6.20 Sales Q/Q-35.30% Oper. Margin- RSI (14)53.04 Volatility4.58% 5.91%
OptionableYes Debt/Eq0.00 EPS Q/Q34.10% Profit Margin- Rel Volume0.46 Prev Close4.88
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume345.08K Price4.74
Recom2.00 SMA200.90% SMA508.00% SMA200-7.86% Volume160,439 Change-2.87%
Apr-29-21Resumed Stephens Overweight $18 → $19
Feb-10-21Initiated Piper Sandler Overweight $15
May-21-20Initiated Raymond James Outperform $20
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Jun-30-16Initiated Rodman & Renshaw Buy $3.50
Sep-24-21 08:00AM  
Sep-17-21 07:06AM  
Sep-15-21 08:00AM  
Sep-09-21 08:00AM  
Sep-08-21 08:00AM  
Aug-05-21 10:55AM  
Jul-29-21 03:05PM  
Jul-22-21 08:00AM  
Jul-19-21 04:01PM  
Jul-14-21 08:00AM  
Jul-06-21 08:00AM  
Jul-01-21 08:00AM  
Jun-28-21 08:45AM  
Jun-21-21 06:00AM  
Jun-10-21 08:00AM  
May-20-21 02:57AM  
May-18-21 08:00AM  
May-13-21 08:00AM  
May-06-21 12:19PM  
May-05-21 12:29PM  
Apr-28-21 08:00AM  
Apr-21-21 11:43AM  
Apr-19-21 08:00AM  
Apr-12-21 08:00AM  
Apr-07-21 04:05PM  
Mar-21-21 04:20AM  
Mar-04-21 08:00AM  
Feb-18-21 08:00AM  
Feb-11-21 04:01PM  
Feb-10-21 10:05AM  
Feb-03-21 08:00AM  
Jan-29-21 04:01PM  
Jan-27-21 08:00AM  
Jan-26-21 04:04PM  
Jan-20-21 08:00AM  
Jan-19-21 11:46PM  
Jan-15-21 08:00AM  
Dec-15-20 10:28PM  
Dec-07-20 08:00AM  
Dec-03-20 04:02PM  
Dec-02-20 08:00AM  
Nov-30-20 10:44AM  
Nov-25-20 10:15AM  
Nov-24-20 04:01PM  
Nov-12-20 08:50AM  
Nov-11-20 07:57AM  
Nov-05-20 09:00AM  
Nov-03-20 08:00AM  
Oct-14-20 10:17PM  
Oct-07-20 06:46AM  
Sep-25-20 08:00AM  
Sep-10-20 08:00AM  
Aug-06-20 08:00AM  
Jul-13-20 08:00AM  
Jul-09-20 09:48AM  
Jul-07-20 09:28PM  
Jul-01-20 04:48PM  
Jun-29-20 08:00AM  
Jun-22-20 04:05PM  
Jun-19-20 11:45AM  
Jun-18-20 09:00AM  
Jun-17-20 04:01PM  
Jun-15-20 08:00AM  
Jun-12-20 08:00AM  
Jun-10-20 08:00AM  
Jun-08-20 08:00AM  
May-11-20 08:00AM  
Apr-28-20 08:00AM  
Apr-21-20 10:53AM  
Apr-06-20 08:00AM  
Mar-29-20 09:02AM  
Mar-17-20 08:57AM  
Feb-24-20 08:00AM  
Feb-20-20 04:05PM  
Feb-18-20 04:05PM  
Feb-13-20 09:15AM  
Feb-12-20 04:15PM  
Feb-07-20 07:32AM  
Jan-27-20 08:00AM  
Jan-17-20 08:00AM  
Dec-30-19 01:12PM  
Dec-20-19 11:10AM  
Dec-19-19 09:34PM  
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
USMAN NASSIMPresident & CEOApr 05Option Exercise4.635,00023,15017,174Apr 07 10:55 AM